Wyeth Premarin DTC Campaign Aims To Reduce Losses
This article was originally published in The Pink Sheet Daily
Executive Summary
The print and broadcast campaign will encourage women to visit their doctors to discuss hormone replacement therapy. Sales for the Premarin family were down 19% to $223 mil. for the second quarter.
You may also be interested in...
Femtrace Launch Planned For Early 2005
Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.
Femtrace Launch Planned For Early 2005
Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.
Wyeth Launches Prempro DTC Campaign Touting Lowest Treatment Dose
The print ad states that hormone therapy is not a "lifelong commitment." This is Wyeth's first full-scale DTC campaign for hormone replacement therapy since the results of the WHI study were released.